| INZY Stock | | | USD 2.81 0.12 4.46% |
Inozyme Pharma financial indicator trend analysis is infinitely more than just investigating Inozyme Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inozyme Pharma is a good investment. Please check the relationship between Inozyme Pharma Other Operating Expenses and its Operating Income accounts. Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For more information on how to buy Inozyme Stock please use our
How to Invest in Inozyme Pharma guide.
Other Operating Expenses vs Operating Income
Other Operating Expenses vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Inozyme Pharma Other Operating Expenses account and
Operating Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Inozyme Pharma's Other Operating Expenses and Operating Income is -0.97. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Operating Income in the same time period over historical financial statements of Inozyme Pharma, assuming nothing else is changed. The correlation between historical values of Inozyme Pharma's Other Operating Expenses and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Inozyme Pharma are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Other Operating Expenses i.e., Inozyme Pharma's Other Operating Expenses and Operating Income go up and down completely randomly.
Correlation Coefficient | -0.97 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Inozyme Pharma. It is also known as Inozyme Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Operating Income
Operating Income is the amount of profit realized from Inozyme Pharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Inozyme Pharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Inozyme Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inozyme Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For more information on how to buy Inozyme Stock please use our
How to Invest in Inozyme Pharma guide.
Selling General Administrative is likely to drop to about 14.5
M in 2024.
Issuance Of Capital Stock is likely to drop to about 63.3
M in 2024
Inozyme Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Inozyme Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inozyme Pharma fundamental ratios Accounts
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to
measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to
predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.